Pupillary responses in non-proliferative diabetic retinopathy.
Park JC, Chen YF, Blair NP, Chau FY, Lim JI, Leiderman YI, Shahidi M, McAnany JJ.
Sci Rep. 2017 Mar 23;7:44987. doi: 10.1038/srep44987.
PMID:28332564
Effect of Chinese Patent Medicines on Ocular Fundus Signs and Vision in Calcium Dobesilate-Treated Persons With Non-Proliferative Diabetic Retinopathy: A Systematic Review and Meta-Analysis.
Zhang Y, An X, Duan L, Jin D, Duan Y, Zhou R, Zhang Y, Kang X, Lian F.
Front Endocrinol (Lausanne). 2022 Mar 14;13:799337. doi: 10.3389/fendo.2022.799337. eCollection 2022.
PMID:35370950
The comparative effects of oral Chinese patent medicines in non-proliferative diabetic retinopathy: A Bayesian network meta-analysis of randomized controlled trials.
Liu Z, Chen Y, Jie C, Wang J, Deng Y, Hou X, Li Y, Cai W.
Front Endocrinol (Lausanne). 2023 Apr 3;14:1144290. doi: 10.3389/fendo.2023.1144290. eCollection 2023.
PMID:37077355
Expanded Field OCT Angiography Biomarkers for Predicting Clinically Significant Outcomes in Non-Proliferative Diabetic Retinopathy.
Ding X, Romano F, Garg I, Gan J, Vingopoulos F, Garcia MD, Overbey KM, Cui Y, Zhu Y, Bennett CF, Stettler I, Shan M, Finn MJ, Vavvas DG, Husain D, Patel NA, Kim LA, Miller JB.
Am J Ophthalmol. 2025 Feb;270:216-226. doi: 10.1016/j.ajo.2024.10.016. Epub 2024 Oct 28.
PMID:39490720
Non-Proliferative Diabetic Retinopathy Is Characterized by Nonuniform Alterations of Peripapillary Capillary Networks.
An D, Chandrasekera E, Yu DY, Balaratnasingam C.
Invest Ophthalmol Vis Sci. 2020 Apr 9;61(4):39. doi: 10.1167/iovs.61.4.39.
PMID:32340031
Non-proliferative diabetic retinopathy symptoms detection and classification using neural network.
Al-Jarrah MA, Shatnawi H.
J Med Eng Technol. 2017 Aug;41(6):498-505. doi: 10.1080/03091902.2017.1358772. Epub 2017 Aug 8.